Healthcare industry

Article - 30/06/2014

Targeting epigenetic DNA modifications for the diagnosis of cancer

Epigenetic DNA modifications have been shown to play a role in carcinogenesis and are therefore a promising target for the early detection of cancer. Dr. Daniel Summerer and his research group at the University of Konstanz have developed a method that enables the direct and site-specific identification of epigenetic changes. The method represents a new approach in the field of epigenetic analysis as well as a major step towards simpler cancer…

Article - 31/03/2014

Lsd1 – a gatekeeper for differentiation onset of embryonic mouse stem cells

Epigenetics is an emerging field of research that studies heritable changes in gene expression that are not caused by changes in the underlying DNA sequence. Prof. Dr. Roland Schüle, Director of Central Clinical Research at the Freiburg University Medical Centre, and his team are specifically focused on epigenetic modifiers that regulate the timely development of placental mouse tissue. Schüle and his team have discovered in mouse embryos that a…

Dossier - 10/03/2014

Cancer therapy and cancer diagnostics

Thanks to improved diagnostics and therapy, today’s cancer patients can live considerably longer than patients several years ago. Nevertheless, some cancers, especially the strongly metastatic ones, are difficult to treat. Therapies targeting immune cells or cancer stem cells could potentially improve the current situation. The early detection and classification of tumours is crucial for the successful treatment of the disease, and molecular…

Article - 29/07/2013

‘Go back to start’ in the field of meiosis

Researchers have long thought they knew exactly how meiosis, meiosis regulators and the complex that forms between homologous chromosomes during meiosis work. The research group headed by Dr. Andrea Pichler from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg has now discovered a new mechanism that plays an important role in meiosis. The study carried out by Pichler and her colleague Dr. Helene Klug has shown why it is…

Article - 10/06/2013

Stem-cell tests to provide protection to unborn babies

The development of unborn babies may already be impaired in the womb by pollutants from the environment food and drugs to which their mothers are exposed. Reliable and informative toxicity tests are necessary in order to assess and prevent the effects toxic substances may have on unborn babies. Biologist Dr. Tanja Waldmann from Konstanz University is developing toxicity test systems based on human embryonic stem cells which contribute to improved…

Article - 13/05/2013

Cardiomyopathies and epigenetic inheritance

Epigenetic mechanisms, along with gene mutations, have been shown to play important roles in the development of heart diseases. Researchers from Heidelberg have discovered that the methylation of two specific genes has an impact on the development of dilated cardiomyopathy. These epigenetic modifications have the potential to be used as molecular markers and improve the diagnosis and therapy of these particular heart diseases.

Dossier - 13/05/2013

The human proteome – the next major goal

The “Human Proteome Project”, a ten-year global initiative that is making a systematic effort to map all human proteins, has moved from the planning to the experimental stage. How significant and how effective the project will be depends on how much the resources offered are used by proteome researchers and on the data that the researchers bring into the project.

Article - 15/04/2013

Price pressure requires new product developments – the "Bioactive Plant Foods" network

The Bioactive Plant Foods network which is coordinated by the Steinbeis-Europa-Zentrum in Stuttgart is focused on developing innovative products that have a positive effect on human health and placing them on the market. Research resolves around the health-promoting effect of amaranth a short-lived plant with catkin-like cymes of densely packed red flowers. More than 20 partners from industry science and marketing have been working together since…

Article - 25/03/2013

Epigenetics for personalised cancer care for women

Every year in the EU, 45,300 women are diagnosed with ovarian cancer and 330,000 with breast cancer. Ovarian cancer has a mortality rate of around 64% and breast cancer around 27%*. The EU-funded research project EpiFemCare aims at improving cancer detection and subsequent patient care. The research project aims to develop blood tests based on epigenetic DNA modifications, i.e. the methylation of the base cytosine, for the identification of…

Article - 28/01/2013

Epigenetics and childhood blood cancer

Juvenile myelomonocytic leukaemia JMML is the most common chronic cancer of the blood in children and tends to have a poor response to chemotherapy. Prof. Dr. Christian Flotho and his team from the Centre of Paediatric and Adolescent Medicine in Freiburg have shown that epigenetic mechanisms play a key role in the pathogenesis of JMML. As part of a German Research Foundation priority programme the researchers from Freiburg are working on…

Article - 19/11/2012

Uncovering the genetics of prostate cancer

The prostate genome project, which is part of the International Cancer Genome Consortium, is focused on the genetic and epigenetic causes of the development and progression of this highly variable cancer and finding markers that enable the reliable diagnosis of the disease. The German research groups involved in the project are coordinated by the German Cancer Research Center and concentrate on prostate cancer patients under 50 years of age, as…

Press release - 12/11/2012

Searching for new strategies against prostate cancer

The European Research Council (ERC) has announced that Roland Schüle, Scientific Director at the Department of Urology, University of Freiburg Medical Centre has been awarded an ERC Advanced Grant. Professor Schüle will receive €2.5 million for a period of 5 years for his research proposal to identify and characterize the molecular and physiological functions of the epigenetic enzyme LSD1 and to explore its role in prostate cancer.

Dossier - 05/11/2012

Cancer – basic research, successes and trends

Science is approaching cancer treatment by using new systems biology approaches and setting up large-scale multidisciplinary projects such as the International Cancer Genome Consortium. Progress in genome, epigenome and gene expression analyses of cancer cells, new insights into the regulation and interaction of cells gained in cooperation with stem cell research and virus research contributes to gaining a causal understanding of cancer. This…

Article - 15/10/2012

ERC Starting Grants 2012: Baden-Württemberg achieves above-average success

On September 10th 2012, the European Research Council (ERC) announced the results of the fifth funding round of its Starting Grants. Baden-Württemberg was awarded 13 grants, and is the state with the largest number of a total of 34 grants awarded to German life sciences researchers. Baden-Württemberg life sciences researchers will be receiving Starting Grants worth around 20 million euros.

Article - 17/09/2012

Biochemisty and the assembly of ammonium machines

Researchers who intend to build enzymes in the laboratory need detailed knowledge about the function of the respective enzymes. Using modern biochemistry methods researchers led by Prof. Dr. Oliver Einsle from the University of Freiburg have in the last few years clarified the atomic structure of a complex bacterial protein that converts atmospheric nitrogen into a form that can be readily used by other organisms. The researchers have recently…

Article - 06/08/2012

varionostic: specialist in epigenetic analyses

Ulm-based varionostic helps epigenetics researchers to obtain information on gene activity. The company is specifically focused on the analysis of methyl groups (-CH3) that are attached to DNA and turn genes on and off. Just as the field of epigenetics, previously only known to insiders, has emerged as a biomedical area of research, the University of Ulm spin-off has matured and grown over the past six years since it was set up.

Press release - 03/08/2012

Dosage compensation in male flies: Balance between sexes

The sex of many organisms is determined by the number of X chromosomes. In humans women have two X chromosomes whereas men have only one but also have an additional Y chromosome. Why this does not result in an imbalance in the expression of important genes on the X chromosome is what researchers at the Max Planck Institute in Freiburg have examined in collaboration with researcher in Cambridge UK. They have been able to show that the initiation…

Press release - 04/06/2012

DFG establishes 20 new Collaborative Research Centres

The support ranges from new therapies for multiple sclerosis via the heroic tradition in ancient time to functional microgels. Attached is a selection of research approaches in science in Baden-Württemberg.

Article - 21/05/2012

Interactions between the genome and the environment

Parental neglect appears to lead to epigenetic changes in children, which result in behavioural problems in later years. This is one issue amongst the many that were addressed at the colloquium “Gene und Umwelt – Wie wir werden, was wir sind” (Genes and the environment – how we become what we are) recently organized by the Daimler and Benz Foundation in Berlin.

Article - 23/04/2012

Iris-Tatjana Kolassa – extreme stress takes a toll on cells

Molecular psychology has huge potential for the future. The discipline has used imaging methods for diagnostic purposes for a long time, but Iris-Tatjana Kolassa, a 33-year-old psychologist from Ulm, is convinced that in future it will increasingly use molecular biology and medicine methods. The idea of remaining blinkered in her own discipline is a notion that is utterly foreign to Kolassa; whenever she senses synergies, whether it be with…

Article - 05/03/2012

Ubiquitin and related molecules do more than just degrade and recycle cellular waste

The proteins of the ubiquitin family have long been regarded as cellular Post-its with to be discarded written on them. However over the last ten years it has become increasingly clear that the proteins of the ubiquitin family that cells use to label defective or unneeded proteins also regulate a broad range of important cellular processes. It has also been found that they are involved in the pathogenesis of cancer and neurodegenerative diseases…

Press release - 01/02/2012

Defects in the packaging of genetic material in malignant brain tumors

Glioblastomas are regarded as particularly aggressive brain tumors. In children with glioblastoma, Heidelberg scientists have now discovered genetic alterations that affect the function of DNA packaging proteins known as histones. In a cell, histones serve as coils around which the DNA wraps. At the same time, histones regulate gene activity. Mutations in histone genes have never before been tied to a disease. The group comprising scientists of…

Article - 16/01/2012

Manfred Jung: drug discovery and the epigenetic code

Prof. Dr. Manfred Jungs team at the University of Freiburg are chemical epigeneticists whose research involves the development of methods that enable them to identify and optimise new therapeutic drugs which are able to alter the epigenetic code of cancer and other cell types. The team use a perfidious worm for their research.

Article - 19/12/2011

Patrick Heun: The DNA tangle and how it is organised

Dr. Patrick Heun and his group of researchers at the Max Planck Institute MPI of Immunobiology and Epigenetics in Freiburg are working on elucidating the spatial organisation of cell nuclei and how the structure of chromosomes is passed on to daughter cells during the division of cells. The researchers have come up with clear proof that the formation of centromeres depends on a single molecule.

Article - 12/12/2011

Comprehensive Biomarker Center GmbH – next-generation biomarkers

Biomarker research has moved on from proteins to nucleic acids where one of the main priorities is the use of microRNA expression profiles. The Heidelberg-based biotech company Comprehensive Biomarker Center GmbH (CBC, formerly febit) has state-of-the-art technologies and the skills and knowledge to advance the development of new nucleic acid biomarkers for complex diseases in cooperation with partners from research and industry.